$TMO

CASPER MARC N sold $161K of TMO

CASPER MARC N (Chairman & CEO) sold 275 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $586.10 ($577.37–$593.32, $0.16M total) across 15 trades on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 10, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest information is the specific open-market sale details: 275 shares sold across 15 trades at a weighted average price of $586.1038, totaling $161,178.54, with holdings after the sale of 123,925 shares.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not indicate intent beyond the plan; without additional context (e.g., multiple consecutive sales, buybacks, or earnings proximity), the signal is weak.

Relevance 3/10Novelty 5/10Timing: Filed after-hours on 2026-08-10, disclosing trades executed 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by its Chairman & CEO.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher CEO/C chairman Casper Marc N sold $161,178 of TMO shares via an open-market sale under a 10b5-1 plan on 2026-08-07.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, but it is explicitly tied to a pre-arranged 10b5-1 plan and the dollar amount is small relative to a mega-cap, reducing signal strength.

Market effects

No clear sector read-through; this is company-specific insider activity without operational or regulatory linkage.

Minimal, as the disclosure is unlikely to move broader US healthcare/life-science tools sentiment.

Limited, since the event is a routine insider sale at a US-listed large-cap.

Counterpoint

Even 10b5-1 sales can coincide with periods of elevated valuation or personal liquidity needs, so traders may still fade near-term strength if flows look persistent.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • CASPER MARC N

    Chairman & CEO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DALMed

CNBC’s ‘Final Trades’: Delta Air, Target, Thermo Fisher Scientific - Delta Air Lines (NYSE:DAL)

CNBC's 'Final Trades' featured picks from analysts, including Delta Air Lines (DAL) for its strong Q2 earnings, Thermo Fisher Scientific (TMO) for its raised FY2026 guidance, and Target (TGT) for its better-than-expected Q2 results. Interactive Brokers (IBKR) was also mentioned for its new Latin America funding solution. DAL +1.4%, TMO -0.1%, TGT -3.8%, IBKR +5.5%.

$BIIBMed

Eyes on Asia: Tanabe Pharma, KYAN Technologies, Biogen

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.